knowledge -WSS

knowledge

author：hotspot 2025-09-27 09:47:18 - browse：2744

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Bristol 'take

focus

WSS

A solution to the after

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

6 phony surgeries that take placebo to the extreme

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

What to expect at HLTH 2023, the health care industry conference

VC firm General Catalyst wants to buy a health system

knowledge

knowledge

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Histogen: Failed biotech offers rare public look inside

Medical records are filled with copy

STAT readers on older presidents, polypills, Medicare, and more

The cancer drug shortage isn’t new — and neither are the solutions

New documents shed light on MD Anderson Cancer Institute feud

Medical leaders decry Supreme Court decision on affirmative action

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Wildfire smoke exposes gaps in outdoor worker protections

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

focus

Medicare inequities exacerbate Puerto Rico’s health disparities

NIH study of ME/CFS points to clear biological hallmarks

Senate panel eyes new effort on drug shortages

NIH study of ME/CFS points to clear biological hallmarks

AI can decode, harness the power of the humane immune system

Ed Silverman on new gene therapies, biosimilars, coffee, and more

leisure time

hotspot

focus

knowledge